The immune response of splenic lymphocytes after cimicifugoside treatment in vitro and pretreatment in vivo.

Abstract

Pretreatment of mouse splenocytes with Shigella lipopolysaccharide and concanavalin A followed by 50 ng/ml of cimicifugoside resulted in a 69% and 31% inhibition of blastogenesis compared to controls. The plaque forming colony assay using sheep erythrocytes (SRBC) showed a decreased number of plaque forming colonies after exposure of the splenic cells to 1 microgram/ml of cimicifugoside. Cimicifugoside, 0.1 mg/mouse i.p. suppressed the anti-SRBC response in the plaque forming assay. The major inhibition of the antibody response occurred when cimicifugoside was administered 1 day before the primary immunization with SRBC. The delayed type hypersensitivity to picryl chloride was suppressed after i.v. administration of cimicifugoside, 1.0-2.0 mg/mouse. The immunosuppressive activity of cimicifugoside is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function.

• Authors: H Hemmi, N Ishida
• Journal: Journal of pharmacobio-dynamics (J Pharmacobiodyn) Vol. 3 Issue 12 Pg. 643-8 (Dec 1980) ISSN: 0386-846X [Print] Japan
• PMID: 7277179 (Publication Type: Journal Article)

Chemical References

• Immunosuppressive Agents
• Mitogens
• Triterpenes
• Lanosterol
• cimicifugoside
• Leucine
• Thymidine

Topics

• Animals
• Erythrocytes (immunology)
• Female
• Hypersensitivity, Delayed
• Immunosuppressive Agents (pharmacology)
• Lanosterol (analogs & derivatives, pharmacology)
• Leucine (metabolism)
• Lymphocyte Activation (drug effects)
• Lymphocytes (drug effects, immunology)
• Male
• Mice
• Mice, Inbred Strains
• Mitogens (pharmacology)
• Spleen (immunology)
• Thymidine (metabolism)
• Triterpenes (pharmacology)